血栓反应素                        
                
                                
                        
                            血栓反应蛋白1                        
                
                                
                        
                            癌症研究                        
                
                                
                        
                            血管生成                        
                
                                
                        
                            生物                        
                
                                
                        
                            基质细胞蛋白                        
                
                                
                        
                            细胞生物学                        
                
                                
                        
                            细胞外基质                        
                
                                
                        
                            血栓反应蛋白                        
                
                                
                        
                            生物化学                        
                
                                
                        
                            酶                        
                
                                
                        
                            金属蛋白酶                        
                
                        
                    
            作者
            
                Pengfei Wang,Zheng Zeng,Caiji Lin,Jiali Wang,Wenwen Xu,Wenqing Ma,Qian Xiang,Huidi Liu,Shu-Lin Liu            
         
                    
        
    
            
            标识
            
                                    DOI:10.2174/1381612826666200128091506
                                    
                                
                                 
         
        
                
            摘要
            
            Thrombospondin-1, an extracellular matrix protein, is the first identified natural angiogenesis inhibitor. Thrombospondin-1 participates in a great number of physiological and pathological processes, including cell-cell and cell-matrix interactions via a number of cell receptors, including CD36 and CD47, which plays a vital role in mediating inflammation and performs a promoting effect in pulmonary arterial vasculopathy and diabetes. Thrombospondin-1 consists of six domains, which combine with different molecules and participate in various functions in cancers, serving as a critical member in diverse pathways in cancers. Thrombospondin-1 works as a cancer promotor in some pathways but as a cancer suppressor in others, which makes it highly possible that its erroneous functioning might lead to opposite effects. Therefore, subdividing the roles of thrombospondin-1 and distinguishing them in cancers are necessary. Complex structure and multiple roles take disadvantage of the research and application of thrombospondin-1. Compared with the whole thrombospondin-1 protein, each thrombospondin- 1 active peptide performs an uncomplicated structure and, nevertheless, a specific role. In other words, various thrombospondin-1 active peptides may function differently. For instance, thrombospondin-1 could both promote and inhibit glioblastoma, which is significantly inhibited by the three type I repeats, a thrombospondin-1 active peptide but promoted by the fragment 167-569, a thrombospondin-1 active peptide consisting of the procollagen homology domain and the three type I repeats. Further studies of the functions of thrombospondin-1 active peptides and applying them reasonably are necessary. In addition to mediating cancerogenesis, thrombospondin-1 is also affected by cancer development, as reflected by its expression in plasma and the cancer tissue. Therefore, thrombospondin-1 may be a potential biomarker for pre-clinical and clinical application. This review summarizes findings on the multiple roles of thrombospondin-1 in cancer processes, with a focus on its use as a potential therapeutic target.
         
            
 
                 
                
                    
                    科研通智能强力驱动
Strongly Powered by AbleSci AI